At this ACR Convergence session, experts provided an overview of the new ACR guideline for juvenile idiopathic arthritis.
Complicated Cases Discussed in Pediatric Thieves Market
At this ACR Convergence 2025 session, clinicians discussed complex and difficult-to-diagnose pediatric cases.
JIA: The Transition to Adult Care
Experts addressed considerations for how to aid patients with juvenile idiopathic arthritis (JIA) in their transition to adult care, specifically highlighting clinical pearls for those with pediatric uveitis and TMJ arthritis.
Let’s Discuss: Insights from the ACR Convergence 2025 Review Course
The Review Course at ACR Convergence 2025 provided a comprehensive update for practitioners. Highlights from the sections on SLE and lupus nephritis, inflammatory brain diseases, drug management of rheumatic diseases and mimics of inflammatory myopathies.
Pediatric Rheumatologist with Lupus Models Hope & Resilience for Her Patients
From educating her colleagues to sharing stories of hope & words of encouragement with her patients, pediatric rheumatology resident Adaobi Ugochukwu draws on her own experience with lupus to ensure that patients receive empathetic, compassionate care.
Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis Released
New global criteria for pediatric CNO aim to boost research & improve care for this rare autoinflammatory bone disease.
New Guidance on Mental Health Screening in Pediatric Rheumatology
Pediatric rheumatologic diseases are characterized by high rates of anxiety & depression known to impact health-related outcomes. CARRA and the ACR developed guidance statements to assess & manage mental health concerns for youths in pediatric rheumatology practice.
Benefits of Early Initiation of Biologic DMARDs in pJIA
The early initiation of biologic disease-modifying anti-rheumatic drugs (DMARDs) may reduce the overall disease burden in patients with polyarticular juvenile idiopathic arthritis (pJIA), according to findings from Ringold et al.
Belimumab Promising for Children with Lupus Nephritis
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…
Trends in the Use of DMARDs for Patients with JIA
Yalamanchili et al. describe how trends in disease-modifying anti-rheumatic drug (DMARD) use have evolved for insured, U.S. patients with juvenile idiopathic arthritis. Overall, the study found that from 2000 to 2022 in this patient population the use of biologic and targeted synthetic DMARDs rose, while the use of conventional synthetic DMARDs declined.
- 1
- 2
- 3
- …
- 14
- Next Page »